Richard Prins Net Worth

The estimated Net Worth of Richard K Prins is at least $4.57 million dollars as of 12 August 2024. Mr. Prins owns over 17,101 units of Amphastar Pharmaceuticals Inc stock worth over $2,301,815 and over the last 16 years he sold AMPH stock worth over $1,959,601. In addition, he makes $313,007 as Lead Independent Director at Amphastar Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Prins AMPH stock SEC Form 4 insiders trading

Richard has made over 46 trades of the Amphastar Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 17,101 units of AMPH stock worth $339,113 on 12 August 2024.

The largest trade he's ever made was exercising 329,583 units of Amphastar Pharmaceuticals Inc stock on 13 March 2024 worth over $14,854,306. On average, Richard trades about 20,251 units every 62 days since 2009. As of 12 August 2024 he still owns at least 51,072 units of Amphastar Pharmaceuticals Inc stock.

You can see the complete history of Mr. Prins stock trades at the bottom of the page.

Richard Prins biography

Richard K. Prins serves as Lead Independent Director of the Company. Since 2008, Mr. Prins has served as a member of our board of directors since February 2002. Since 2008, Mr. Prins has been a private investor and involved in various charitable organizations. Mr. Prins also volunteers as acting head of U.S. Operations for Advancing Native Missions and serves on the board of directors of India Globalization Capital, Inc. Mr. Prins was the Director of Investment Banking for FBW, from 1996 until June 2008 when FBW was acquired by Royal Bank of Canada and served as a consultant to Royal Bank of Canada Capital Markets through December 2008. Prior to FBW, Mr. Prins was a Managing Director from July 1988 to April 1996 at Crestar Bank (now SunTrust Bank) in charge of mergers and acquisitions. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp., where he held various positions until July 1988. Mr. Prins received a B.A. in liberal arts from Colgate University and an M.B.A. from Oral Roberts University.

What is the salary of Richard Prins?

As the Lead Independent Director of Amphastar Pharmaceuticals Inc, the total compensation of Richard Prins at Amphastar Pharmaceuticals Inc is $313,007. There are 10 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of $5,969,740.

How old is Richard Prins?

Richard Prins is 62, he's been the Lead Independent Director of Amphastar Pharmaceuticals Inc since 2019. There are 8 older and 7 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.

Insiders trading at Amphastar Pharmaceuticals Inc

Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over $72,457,295 worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth $921,987 . The most active insiders traders include Jack Y.Luo Mary Z. Zhang, Richard K Prins et William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,459,051. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth $139,410.

What does Amphastar Pharmaceuticals Inc do?

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int

Complete history of Mr. Prins stock trades at Amphastar Pharmaceuticals Inc et IGC Pharma Inc

Amphastar Pharmaceuticals Inc executives and stock owners

Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jack Zhang,
  President, Chief Executive Officer, Chief Scientific Officer, Director
• Mary Luo,
  Chief Operating Officer, Chief Scientist and Chairman of the Board
• Dr. Yongfeng Zhang,
  Co-founder, Pres, CEO, Chief Scientific Officer & Director
• William Peters,
  Chief Financial Officer, Senior Vice President, Treasurer and President of International Medication Systems, Limited
• Dr. Ziping Luo,
  Chairman, Chief Scientist & COO
• Rong Zhou,
  Executive Vice President - Production Center and President of Armstrong Pharmaceuticals, Inc.
• William J. Peters M.B.A.,
  CFO, Treasurer & Exec. VP of Fin.
• Rong Zhou,
  Exec. VP of Production Center
• Jacob Liawatidewi M.B.A.,
  Exec. VP of Corp. Admin. Center, Sales & Marketing and Corp. Sec.
• Diane Gerst,
  Director
• Richard Prins,
  Lead Independent Director
• Richard Koo,
  Independent Director
• Howard Lee,
  Independent Director
• Michael Zasloff,
  Independent Director
• Floyd Petersen,
  Independent Director
• Jacob Liawatidewi,
  Senior Vice President of Sales and Marketing, Corporate Administration Center, Corporate Secretary
• Peter Langosh,
  VP of Operational Improvement and VP of Internal Audit
• Tony Marrs,
  Sr. VP of Regulatory Affairs and Clinical Operations
• Dan Dischner,
  VP of Corp. Communications
• Stephen B. Shohet,
  Director
• Gayle Deflin,
  
• Physics & Chemistry Laborat...,
  10% owner
• Mary Z.Zhang Jack Y. Luo,
  COO,Chief Scientist & ChairmanCEO & Chief Scientific Officer
• Jason B. Shandell,
  President and General Counsel
• Marilyn J. Purchase,
  Corp. Exec. VP of Operations
• David Maris,
  Director
• Jack Y.Luo Mary Z.Applied P...,
  CEO & Chief Scientific OfficerCOO,Chief Scientist & Chairman
• Yakob Liawatidewi,
  EVP CORP ADMIN CENTER